Skip to main content

medroxyprogesterone acetate 104 mg/.65mL Medicare Part D Coverage

Brand name: Depo-SubQ Provera
Dosage form
INJECTION, SUSPENSION
Route
SUBCUTANEOUS
100%
of Medicare Part D plans
cover medroxyprogesterone acetate
5,529 of 5,530 plans
2.9
Avg. formulary tier
$44.00
Median 30-day copay
$0.00–$88.00
Copay range

Formulary Tier Distribution

How Medicare Part D plans classify medroxyprogesterone acetate. Lower tiers = lower copays.

Tier 1 - Preferred Generic 3%
163 plans • avg $0.00/mo
Tier 2 - Generic 1%
52 plans • avg $16.46/mo
Tier 3 - Preferred Brand 96%
5,307 plans • avg $5.94/mo
Tier 4 - Non-Preferred Drug 0%
7 plans • avg $82.86/mo

Find the cheapest plan for medroxyprogesterone acetate

Enter your ZIP code to compare every plan in your area side-by-side.

Compare Plans for medroxyprogesterone acetate →

Get medroxyprogesterone acetate Delivered to Your Door

Compare prices and get discounts from trusted online pharmacies

DrugCovered may earn commissions from pharmacy purchases. Prices and availability vary. Always consult your doctor before starting or changing medications.

medroxyprogesterone acetate Medicare Coverage by State

Coverage rates and average costs vary significantly by state. Click a state to see the specific plans available there.

Frequently Asked Questions about medroxyprogesterone acetate

100% of Medicare Part D plans cover medroxyprogesterone acetate. It is most commonly placed on Tier 3. Coverage varies by plan and geographic area.

The median 30-day copay for medroxyprogesterone acetate on Medicare Part D is $44.00 at a preferred pharmacy. Costs range from $0.00 to $88.00 depending on the plan.

medroxyprogesterone acetate is placed on Tier 3 by most Medicare Part D plans. Lower tier numbers generally mean lower copays.

0% of plans require prior authorization for medroxyprogesterone acetate. Prior authorization means your doctor must confirm the drug is medically necessary before the plan will cover it.

Coverage statistics based on CMS formulary data for plan year 2026. Data updated regularly. Methodology →